Nexavar is a brand-name medication that contains the active ingredient sorafenib. Sorafenib belongs to the class of multikinase inhibitors and is used as an oncology support therapy for several advanced solid tumours. In Hong Kong, Nexavar is available by prescription only in 200 mg tablet form and is regulated by the Hong Kong Department of Health in line with international standards.
Sorafenib blocks multiple kinases that are essential for tumour growth and blood-vessel formation. Its key actions include:
These mechanisms together limit tumour expansion and can help stabilise disease in patients with advanced cancers.
Nexavar is approved for the following indications in Hong Kong and many other jurisdictions:
These approvals are based on clinical trials that demonstrated improved progression-free survival compared with placebo in each tumour type.
Current peer-reviewed evidence supports limited off-label uses of sorafenib, such as investigational treatment of certain sarcomas or metastatic melanoma. These applications are not approved by regulatory agencies and should only be considered within clinical trial protocols or under strict medical supervision. Off-label use requires medical supervision and individualized risk assessment.
This article provides educational information about Nexavar and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Concurrent use with other tyrosine-kinase inhibitors may increase toxicity and is generally avoided unless specifically prescribed in a clinical trial. Always inform your oncologist of all current medications.
Contact your healthcare provider promptly; dose interruption or reduction is often recommended, and topical steroids or dose-adjusted systemic therapy may be prescribed.
Patients with mild hepatic impairment (Child-Pugh A) can usually receive the standard dose, but liver function must be monitored closely for any elevation in enzymes.
Both target VEGFR pathways, but sorafenib also inhibits RAF kinases, giving it a broader spectrum of action. Comparative efficacy depends on the tumour type and should be discussed with an oncologist.
Yes, but keep the medication in its original packaging with a copy of the prescription. Some countries may require a doctor’s note; check local regulations before travel.
Sorafenib can raise blood pressure; regular home monitoring is advised, and any persistent elevation should be reported to your physician for possible antihypertensive therapy.
Limit grapefruit juice, as it can inhibit CYP3A4 and increase drug levels. No specific dietary restrictions exist beyond moderate alcohol consumption, especially in patients with liver disease.
The expiry date is printed on the container; tablets remain stable for up to two years when stored at room temperature, protected from moisture and light.
Coverage varies by private and public insurers. Contact your insurer directly and provide the prescription details to confirm reimbursement eligibility.
Sorafenib tablets are not officially approved for compounding. Any alteration should be performed only by a certified pharmacy under a physician’s order, considering stability and dosing accuracy.
